Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14

  • Tabrecta demonstrated an overall response rate of 68% and 41% in treatment-naive and previously treated non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping (METex14) respectively
     
  • Lung cancer is the most common type of cancer in Japan and approximately 3,000 patients are diagnosed with METex14 metastatic NSCLC, a particularly aggressive form of the disease, in Japan each year1-2
     
  • Japan follows US approval earlier this year and demonstrates the company’s commitment to reimagining medicine for lung cancer …
/by

Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options

Basel, June 29, 2020 — Novartis Pharma K.K. (“Novartis Pharma”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) simultaneously approved five new treatment options for Japanese patients:

  • Tabrecta™ (capmatinib, formerly INC280), an oral MET inhibitor for MET exon 14 skipping (METex14) mutation-positive advanced and/or recurrent unresectable non-small cell lung cancer (NSCLC),
  • Entresto® (sacubitril valsartan sodium hydrate) in chronic heart failure,
  • Mayzent® (siponimod fumaric acid …
/by